Description of the eviDence collection methoD The literature review of scientific articles in this guideline was held in the databases Medline, Cochrane and SciELO. The search for evidence came from actual clinical scenarios and used keywords (MeSH terms) grouped in the following syntax: adult dominant polycystic kidney disease; adult recessive polycystic kidney disease; PKD mutation; PKDH1 mut...

要旨: 常染色体優性遺伝嚢胞腎(ADPKD)は 進行性の腎機能低下が主要な病態であるが, その予後は従 来いわれているように 「診断後10年で腎不全に到る」ものでもなく, 腎不全が不可避でもない. 本邦で の透析導入時平均年齢は52~56歳 であるが, 透析に移行しない者も含めると, おおよそ平均73歳で終末 期腎不全に到る. 60歳代で透析を受ける割合は約40%で あり, 本邦のADPKDの 予後は欧米よりも若干 良好である可能性がある. ADPKDの 遺伝子は第16染色体の短腕上のα-globin遺伝子の近くに存在することが確かめられてい る. この遺伝子(PKD1)に よるADPKDと, PKD1の 関与が証明されないADPKDで は, 腎機能の予 後が異なることが報告されている. 高血圧は約60%に 認められる. 嚢胞の圧迫によって腎動脈が狭細化し, レニン-ア ンギオテソシ...

BACKGROUND A large proportion of patients with autosomal dominant polycystic kidney disease (ADPKD) suffers from polycystic liver disease. Symptoms arise when liver volume increases. The somatostatin analogue lanreotide has proven to reduce liver volume in patients with polycystic liver disease. However, this study also included patients with isolated polycystic liver disease (PCLD). The RESOLV...

Gene dosage effects have emerged as playing a central role in the pathogenesis of polycystic kidney disease. Yet, how gene dosage can ultimately have an impact on the formation of kidney cysts remains unknown. In this commentary we review the evidence for the role of gene dosage effects versus the "2-hit" mutation model in polycystic kidney disease (PKD), and also discuss how gene networks may ...

We report on a 52-year-old woman who presented with polycystic disease. Both of her kidneys had been removed and she had undergone one failed kidney transplantation. She had severe symptoms from the polycystic liver. The diseased liver and kidney were both treated successfully by performing a combined liver and kidney transplantation.

Renal tubular cysts arise in several inherited human disorders which include autosomal dominant polycystic kidney disease (ADPKD), as well as rarer disorders such as autosomal recessive polycystic kidney disease (ARPKD) nephronophthisis and medullary cystic kidney. Despite their genetic, clinical and histopathological heterogeneity, all these diseases involve a dilation of tubules leading to cy...

The lack of reliable data on frequency, age of onset, survival, spontaneous mutation rate and prognosis in autosomal dominant polycystic kidney disease is a continual source of frustration to physicians involved in counselling patients and their relatives. The only major study to address all of these issues in a defined population was presented by Dalgaard as a 251-page doctoral thesis in 1957 ...

INTRODUCTION The most common hereditary kidney condition is autosomal dominant polycystic kidney disease. It is the cause of 5-10% of end-stage renal disease. Its symptoms are generally late-onset, typically leading to development of hypertension and chronic kidney disease. Ultrasonography is the imaging modality of choice in its diagnosis and management. The aim of this study is to determine t...